Inventor · disambiguated record
Shixia Wang
Also filed as: WANG SHIXIA
11 granted patents·12 pending applications·85 citations·filing 2003–2023
88Inventor score
Files withCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD10UNIV MASSACHUSETTS8LU SHAN2CARDOZO TIMOTHY1UNIV MASSACHUSETTS A MASSACHUS1
Top patents by PatentIndex Score
23 records- 0196US7566454B2Influenza nucleic acids, polypeptides, and uses thereofUNIV MASSACHUSETTS·Filed 2006·Granted Jul 28, 2009·37 cites·18 claims
- 0288US7901690B2Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methodsUNIV MASSACHUSETTS·Filed 2003·Granted Mar 8, 2011·33 cites·34 claims
- 0387US7847085B2Recombinant HIV-1 gp120 immunogen with three different V3 loops from viruses of different cladesUNIV NEW YORK·Filed 2007·Granted Dec 7, 2010·8 cites·43 claims
- 0484US10124060B2Compositions and methods to treat aidsUNIV MASSACHUSETTS·Filed 2017·Granted Nov 13, 2018·1 cites·20 claims
- 0580US9675687B2Compositions and methods to treat AIDSUNIV MASSACHUSETTS·Filed 2014·Granted Jun 13, 2017·1 cites·21 claims
- 0678US9534020B2Immunogenic polypeptides comprising a modified loop peptide presenting the HIV-1 GP120 3074 mAb epitope and scaffold proteins containing said peptideCARDOZO TIMOTHY·Filed 2011·Granted Jan 3, 2017·3 cites·12 claims
- 0773US11690906B2Compositions and methods to treat aidsUNIV MASSACHUSETTS·Filed 2020·Granted Jul 4, 2023·0 cites·10 claims
- 0873US10869921B2Compositions and methods to treat AIDSUNIV MASSACHUSETTS·Filed 2018·Granted Dec 22, 2020·0 cites·20 claims
- 0968US7807180B2Poxvirus methods and compositionsUNIV MASSACHUSETTS·Filed 2007·Granted Oct 5, 2010·1 cites·9 claims
- 1064US11583508B2Use of mitoxantrone liposome for treating non-Hodgkin's lymphomaCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2019·Granted Feb 21, 2023·1 cites·15 claims
- 1162US2025288535A1Instant nanoparticle composition and preparation method thereforCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2023·Application pending·0 cites
- 1261US2009291472A1Influenza nucleic acids, polypeptides, and uses thereofUNIV MASSACHUSETTS A MASSACHUS·Filed 2009·Application pending·0 cites
- 1357US2024269092A1Use of mitoxantrone hydrochloride liposome in preparation of drugs for treating advanced solid tumorsCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2022·Application pending·0 cites
- 1454US2024024257A1Use of mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisoneCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2021·Application pending·0 cites
- 1554US2024122875A1Use of mitoxantrone hydrochloride liposomeCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2022·Application pending·0 cites
- 1652US2024058280A1Use of mitoxantrone hydrochloride liposomeCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2021·Application pending·0 cites
- 1752US2023293454A1Use of mitoxantrone hydrochloride liposome and pegaspargaseCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2021·Application pending·0 cites
- 1851US2023078702A1Use of mitoxantrone hydrochloride liposome for treating breast cancerCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2021·Application pending·0 cites
- 1950US2020060982A1Purified therapeutic nanoparticles and preparation methods thereofCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2019·Application pending·0 cites
- 2048US2004266713A1Methods and compositions for solid tumor treatmentLU SHAN·Filed 2004·Application pending·0 cites
- 2148US2007270361A1Sars Nucleic Acids, Proteins, Vaccines, and Uses ThereofLU SHAN·Filed 2004·Application pending·0 cites
- 2245US2011171258A1Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methodsUNIV MASSACHUSETTS·Filed 2011·Application pending·0 cites
- 2344US10500165B2Purified therapeutic nanoparticles and preparation methods thereofCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2015·Granted Dec 10, 2019·0 cites·28 claims
Join the waitlist — get patent alerts
Get an alert when Shixia Wang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →